Clinical experience of IL-6 blockade in rheumatic diseases—Implications on IL-6 biology and disease pathogenesis - ScienceDirect
Why tocilizumab could be an effective treatment for severe COVID-19? | Journal of Translational Medicine | Full Text
Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia | SpringerLink
Frontiers | Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)? | Medicine
IL-6 antagonists may have a role in fighting COVID-19 after all - The Cancer Letter
Subcutaneous formulation of tocilizumab for treatment of rheumatoid arthritis | Therapeutic Delivery
Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up - eClinicalMedicine
A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases | SpringerLink
How is Actemra® (tocilizumab) for GCA believed to work?
Actemra | Uses, Safety Info & Comparison to Other RA Drugs
Risk of reactivation of hepatitis B virus (HBV) and tuberculosis (TB) and complications of hepatitis C virus (HCV) following Tocilizumab therapy: A systematic review to inform risk assessment in the COVID era
Outlook of IL-6 signaling blockade for COVID-19 pneumonia | Inflammation and Regeneration | Full Text
Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT) - Clinical Microbiology and Infection
JCI - IL-6 polymorphisms: a useful genetic tool for inflammation research?
Actemra (Tocilizumab) Shortage Is Still Affecting Rheumatology Patients
Figure 5 | The Roles of Interleukin-6 in the Pathogenesis of Rheumatoid Arthritis
Rheumatoid_Arthritis_Treatments_with_Biologics
Tocilizumab-Atlizumab Overview - Creative Biolabs
Immunomodulation as a potent COVID-19 pharmacotherapy | JIR
Mechanism of action of tocilizumab in RA (bathtub theory). Notes: The... | Download Scientific Diagram
![The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review [PeerJ]](https://dfzljdn9uc3pi.cloudfront.net/2020/10322/1/fig-3-full.png "The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review [PeerJ]")
The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review [PeerJ]
Subcutaneous formulation of tocilizumab for treatment of rheumatoid arthritis | Therapeutic Delivery
Tocilizumab Raises GI Risks in Rheumatoid Arthritis | MedPage Today
